tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Divi’s Laboratories Reports Stable Q1 Financial Results for 2025

Story Highlights
Divi’s Laboratories Reports Stable Q1 Financial Results for 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Divi’s Laboratories Limited ( (IN:DIVISLAB) ) has shared an announcement.

Divi’s Laboratories Limited has announced its unaudited financial results for the quarter ended June 30, 2025, reporting a total income of 2,476 crore and a profit of 557 crore. The results, approved by the Board of Directors, indicate a stable financial performance with no discontinued operations, reflecting the company’s ongoing commitment to its core pharmaceutical manufacturing operations.

More about Divi’s Laboratories Limited

Divi’s Laboratories Limited is a prominent company in the pharmaceutical industry, specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical Ingredients. The company focuses on a single reportable business segment, maintaining a strong presence in the pharmaceutical manufacturing sector.

Average Trading Volume: 13,601

Technical Sentiment Signal: Buy

Current Market Cap: 1688.1B INR

For detailed information about DIVISLAB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1